Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navtemadlin in relapsed/refractory SCLC
NCT05027867Phase 2Terminated
- Sponsor
- Kartos Therapeutics
- Start
- Dec 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of navtemadlin in small cell lung cancer (SCLC), sponsored by Kartos Therapeutics. Started Dec 2021; status: terminated.
02
Drugs
navtemadlin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05027867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05027867.